227.54
price down icon0.21%   -0.49
after-market Handel nachbörslich: 228.40 0.86 +0.38%
loading
Schlusskurs vom Vortag:
$228.03
Offen:
$227
24-Stunden-Volumen:
3.72M
Relative Volume:
0.70
Marktkapitalisierung:
$401.96B
Einnahmen:
$58.33B
Nettoeinkommen (Verlust:
$3.73B
KGV:
108.29
EPS:
2.1013
Netto-Cashflow:
$18.24B
1W Leistung:
-1.66%
1M Leistung:
+3.14%
6M Leistung:
+18.30%
1J Leistung:
+19.96%
1-Tages-Spanne:
Value
$224.31
$228.40
1-Wochen-Bereich:
Value
$224.31
$232.16
52-Wochen-Spanne:
Value
$163.81
$244.81

Abbvie Inc Stock (ABBV) Company Profile

Name
Firmenname
Abbvie Inc
Name
Telefon
(847) 932-7900
Name
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Mitarbeiter
55,000
Name
Twitter
@abbvie
Name
Nächster Verdiensttermin
2025-04-25
Name
Neueste SEC-Einreichungen
Name
ABBV's Discussions on Twitter

Vergleichen Sie ABBV mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.54 402.83B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
LLY
Lilly Eli Co
820.10 740.84B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.93 458.49B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
123.43 250.00B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.03 219.80B 63.43B 16.42B 14.72B 6.4861

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-14 Herabstufung Erste Group Buy → Hold
2025-10-01 Herabstufung HSBC Securities Buy → Hold
2025-09-17 Hochstufung Berenberg Hold → Buy
2025-08-12 Fortgesetzt Piper Sandler Overweight
2025-08-07 Hochstufung Daiwa Securities Neutral → Outperform
2025-05-14 Herabstufung Citigroup Buy → Neutral
2025-04-22 Eingeleitet Cantor Fitzgerald Overweight
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-12-05 Herabstufung Daiwa Securities Outperform → Neutral
2024-11-22 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-04 Hochstufung Argus Hold → Buy
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-06-05 Hochstufung HSBC Securities Hold → Buy
2024-05-17 Eingeleitet Cantor Fitzgerald Overweight
2024-01-29 Hochstufung William Blair Mkt Perform → Outperform
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-12-11 Hochstufung Goldman Neutral → Buy
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-10-30 Hochstufung Barclays Equal Weight → Overweight
2023-10-20 Fortgesetzt UBS Neutral
2023-09-29 Eingeleitet Raymond James Outperform
2023-07-25 Eingeleitet William Blair Mkt Perform
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-05 Herabstufung Argus Buy → Hold
2023-03-01 Eingeleitet Guggenheim Buy
2023-02-22 Herabstufung Wolfe Research Outperform → Peer Perform
2023-02-10 Hochstufung SVB Securities Underperform → Market Perform
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-11-08 Herabstufung Societe Generale Buy → Hold
2022-08-01 Herabstufung Atlantic Equities Overweight → Neutral
2022-05-23 Eingeleitet SVB Leerink Underperform
2022-05-06 Herabstufung Daiwa Securities Outperform → Neutral
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2022-02-28 Herabstufung UBS Buy → Neutral
2022-02-03 Bestätigt BMO Capital Markets Outperform
2022-02-03 Bestätigt Barclays Equal Weight
2022-02-03 Bestätigt BofA Securities Neutral
2022-02-03 Bestätigt Goldman Neutral
2022-01-13 Eingeleitet Redburn Buy
2022-01-12 Bestätigt BMO Capital Markets Outperform
2021-12-09 Fortgesetzt Wells Fargo Overweight
2021-11-23 Hochstufung Societe Generale Hold → Buy
2021-07-27 Fortgesetzt Truist Buy
2021-04-07 Fortgesetzt RBC Capital Mkts Outperform
2020-11-10 Fortgesetzt Bernstein Outperform
2020-09-29 Eingeleitet Berenberg Hold
2020-06-23 Hochstufung Atlantic Equities Neutral → Overweight
2020-06-09 Hochstufung Wolfe Research Peer Perform → Outperform
2020-06-02 Hochstufung Argus Hold → Buy
2020-05-18 Fortgesetzt BofA/Merrill Neutral
2020-05-12 Hochstufung JP Morgan Neutral → Overweight
2020-05-11 Fortgesetzt Morgan Stanley Overweight
2020-04-20 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2020-03-23 Herabstufung Societe Generale Buy → Hold
2020-02-27 Eingeleitet Barclays Equal Weight
2020-02-06 Eingeleitet Mizuho Buy
2020-01-07 Eingeleitet RBC Capital Mkts Sector Perform
2019-12-26 Bestätigt Cowen Outperform
2019-09-26 Hochstufung Citigroup Neutral → Buy
2019-08-20 Hochstufung Piper Jaffray Neutral → Overweight
2019-06-27 Hochstufung Wolfe Research Underperform → Peer Perform
2019-06-26 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-05-28 Eingeleitet Goldman Neutral
2019-04-29 Hochstufung BMO Capital Markets Underperform → Market Perform
Alle ansehen

Abbvie Inc Aktie (ABBV) Neueste Nachrichten

pulisher
Oct 28, 2025

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) – Clinical Overview, Companies, Therapeutic Assessment, Treatment Approaches, Pipeline Insights | AbbVie, Sanofi - Barchart.com

Oct 28, 2025
pulisher
Oct 28, 2025

AbbVie: Deep Discount Before Earnings (NYSE:ABBV) - Seeking Alpha

Oct 28, 2025
pulisher
Oct 28, 2025

Should You Buy AbbVie Stock Ahead of Q3 Earnings Report? - sharewise.com

Oct 28, 2025
pulisher
Oct 28, 2025

Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM - PR Newswire

Oct 28, 2025
pulisher
Oct 28, 2025

Want Decades of Passive Income? Buy This Index Fund and Hold It Forever. - The Motley Fool

Oct 28, 2025
pulisher
Oct 28, 2025

Will AbbVie Inc. stock attract more institutional investorsEarnings Overview Summary & Capital Protection Trade Alerts - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

Can AbbVie Inc. stock attract analyst upgrades2025 Year in Review & Risk Controlled Swing Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest - Barchart.com

Oct 27, 2025
pulisher
Oct 27, 2025

AbbVie Defends Challenge Of Colorado's Discount Drug Law - Law360

Oct 27, 2025
pulisher
Oct 27, 2025

Can AbbVie Inc. stock withstand economic slowdownEarnings Overview Summary & Fast Exit and Entry Trade Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will AbbVie Inc. (Common Stock) (4AB0) stock extend growth storyPortfolio Gains Report & Free Weekly Chart Analysis and Trade Guides - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Can AbbVie Inc. stock surprise markets with earningsPortfolio Growth Summary & Real-Time Chart Pattern Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

What's in Store for These 5 Pharma Bigwigs This Earnings Season? - TradingView

Oct 27, 2025
pulisher
Oct 27, 2025

Pigmentation Disorders Treatment Market Is Booming Worldwide 2025-2032 |Abbvie Inc., Edesa Biotech, Inc., Amgen - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is AbbVie Inc. stock a buy on dips2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is AbbVie Inc. stock resilient to inflationJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Ophthalmic Drugs Market Set for Dynamic Growth with Key Players Abbvie Inc. (Allergan Plc), Alcon, Inc., Novartis AG - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Fish Skin Disease Market to Witness Remarkable Growth With GSK - openPR.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will AbbVie Inc. (Common Stock) (4AB0) stock test record highs in 20252025 Top Gainers & High Yield Stock Recommendations - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How AbbVie Inc. stock performs in rising dollar environmentWeekly Earnings Recap & Daily Oversold Bounce Ideas - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

How sentiment analysis helps forecast AbbVie Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com

Oct 26, 2025
pulisher
Oct 26, 2025

Why AbbVie Inc. (4AB) stock stays on top picksPortfolio Risk Summary & Technical Pattern Alert System - newser.com

Oct 26, 2025
pulisher
Oct 25, 2025

How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts - Yahoo Finance

Oct 25, 2025
pulisher
Oct 25, 2025

AbbVie Stock Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com

Oct 25, 2025
pulisher
Oct 24, 2025

AbbVie’s ABBV-932 Study: A New Hope for Bipolar Disorder Treatment? - TipRanks

Oct 24, 2025
pulisher
Oct 24, 2025

Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It? - sharewise.com

Oct 24, 2025
pulisher
Oct 23, 2025

AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth - sharewise.com

Oct 23, 2025
pulisher
Oct 23, 2025

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism - ts2.tech

Oct 23, 2025
pulisher
Oct 23, 2025

Wolfe Research Adjusts AbbVie Price Target to $275 From $235, Maintains Outperform Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

United States Breast Reconstruction Market Growth Trends and Forecast Report 2025-2033, Profiles of Mentor Worldwide, AbbVie, Integra, Sientra, Stryker, Establishment Labs, RTI Surgical, TELA Bio - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

How AbbVie Inc. (Common Stock) (4AB0) stock behaves under inflation pressureEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

Analyst Says He Likes AbbVie (ABBV) Amid ‘Attractive’ Valuation - Insider Monkey

Oct 22, 2025
pulisher
Oct 22, 2025

Will Rinvoq’s Superiority Over Humira in SELECT-SWITCH Trial Change AbbVie's (ABBV) Narrative - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

AbbVie Inc. (ABBV): A Bull Case Theory - Insider Monkey

Oct 22, 2025

Finanzdaten der Abbvie Inc-Aktie (ABBV)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general JNJ
$186.93
price down icon 1.77%
drug_manufacturers_general NVS
$123.43
price down icon 4.42%
drug_manufacturers_general MRK
$87.03
price down icon 1.10%
drug_manufacturers_general NVO
$52.05
price down icon 1.59%
$292.09
price up icon 0.32%
Kapitalisierung:     |  Volumen (24h):